Trastuzumab deruxtecan
Trastuzumab deruxtecan (T-DXd) is an antibody–drug conjugate directed against human EGFR 2 (Human epidermal growth factor receptor 2 (HER2)), the protein encoded by Human epidermal growth factor receptor 2 (HER2).
Trastuzumab deruxtecan (T-DXd) is an antibody–drug conjugate directed against human EGFR 2 (Human epidermal growth factor receptor 2 (HER2)), the protein encoded by Human epidermal growth factor receptor 2 (HER2). It combines a trastuzumab-derived monoclonal antibody with deruxtecan, a topoisomerase I inhibitor, through a cleavable linker. After binding Human epidermal growth factor receptor 2 (HER2) on tumor cells, the conjugate is internalized and releases its cytotoxic payload, thereby causing DNA damage and cell death. Its activity is therefore dependent on both Human epidermal growth factor receptor 2 (HER2) recognition and delivery of the intracellular chemotherapy payload.
T-DXd is used as a Human epidermal growth factor receptor 2 (HER2)-directed treatment across several solid Tumors, including breast cancer, gastric and esophageal Cancer, and selected Human epidermal growth factor receptor 2 (HER2)-altered lung Cancers. Its clinical and biological significance is influenced by variation in Human epidermal growth factor receptor 2 (HER2) protein expression, gene amplification, and intratumoral heterogeneity. HER2-low or Human epidermal growth factor receptor 2 (HER2)-negative subclones may affect treatment response and resistance, while alternative treatment strategies include Human epidermal growth factor receptor 2 (HER2) tyrosine-kinase inhibitors such as zongertinib. As an antibody–drug conjugate, T-DXd differs mechanistically from ado-trastuzumab emtansine and from immune checkpoint inhibitors such as nivolumab, atezolizumab, and durvalumab.
Where the papers sit
11 papers from the last 6 months study trastuzumab deruxtecan directly · updated from PubMed 16 Nov 2026
Study type 1 clinical trial · 4 observational · 2 human data · 4 preclinical
Themes 3 themes
-
Breast Cancer Treatment Response
Treatment response in metastatic breast cancer is being linked to both tumor biology and patient selection. S100-RAGE signaling emerges as a mechanism of intrinsic trastuzumab deruxtecan resistance, while activating ERBB2 mutations may improve drug internalization in HER2-nonamplified disease. Rechallenge is being explored, alongside models using histologic, MRI and clinical features to predict chemoresistance. Baseline serum albumin may help identify patients at risk for severe toxicity, while residual disease assays extend response assessment into triple-negative breast cancer.
6 papers · 54.5%
-
HER2-Altered Lung Cancer
HER2-altered advanced NSCLC is moving toward biomarker-directed sequencing of antibody-drug conjugates and kinase inhibitors. Trastuzumab deruxtecan is being evaluated against conventional first-line approaches in real-world practice, while ERBB2 blockade can overcome cetuximab resistance caused by an EGFR S442 ectodomain mutation. Rechallenge with zongertinib after trastuzumab deruxtecan highlights the need to define treatment order and resistance states. The evidence remains early, combining case-level observations with multicenter outcomes.
3 papers · 27.3%
-
Brain Tumor Drug Delivery
Delivering antibody-drug conjugates to brain tumors remains constrained by the blood–brain barrier. Focused ultrasound is being developed to improve CNS exposure, with quantitative pharmacokinetic modeling supporting translational use. Related work is moving toward combining trastuzumab deruxtecan with radiotherapy rather than treating safety as a fixed barrier. Temozolomide, trastuzumab and ado-trastuzumab emtansine provide comparator or combination contexts, but the central question is more effective intracranial treatment.
2 papers · 18.2%
Papers
The 11 papers from the last 6 months that study trastuzumab deruxtecan directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Breast Cancer Treatment Response (6)
- Baseline Serum Albumin Is Associated With Severe Adverse Events During Trastuzumab Deruxtecan Treatment in Metastatic Breast Cancer. Anticancer research · 27 Oct 2026 PMID 42946412
- Predicting Chemoresistance in HER2-low Breast Cancer: Histologic Grade, MRI Non-mass Enhancement, and Clinical T Stage. Anticancer research · 1 Oct 2026 PMID 42823184
- ERBB2 Activating Mutations Promote Enhanced Internalization and Activity of Trastuzumab Deruxtecan in HER2-Nonamplified Metastatic Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research · 9 Sept 2026 PMID 42714867
- Trastuzumab deruxtecan rechallenge in HER2-positive metastatic breast cancer: EN-SEMBLE. Breast (Edinburgh, Scotland) · 10 Aug 2026 PMID 42575050
- Molecular evaluation of residual disease following neoadjuvant chemotherapy in triple-negative breast cancer CALGB 40603 (Alliance). The Journal of clinical investigation · 4 Aug 2026 PMID 42550611
- Targetable S100-RAGE Signaling Mediates Intrinsic Trastuzumab Deruxtecan Resistance in Metastatic Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research · 17 Jul 2026 PMID 42467226
HER2-Altered Lung Cancer (3)
- First-line treatment outcomes in HER2-altered advanced NSCLC: a real-world multi-center study comparing trastuzumab deruxtecan with conventional therapies and analysis by HER2/EGFR co-alteration status. BMC cancer · 13 Oct 2026 PMID 42864628
- Rechallenge with zongertinib after trastuzumab deruxtecan in HER2-mutant lung cancer: A case report. Lung cancer (Amsterdam, Netherlands) · 13 Jun 2026 PMID 42287786
- EGFR S442 ectodomain mutation confers cetuximab resistance that can be overcome by ERBB2 blockade with trastuzumab-deruxtecan. Cancer letters · 23 May 2026 PMID 42176792
Brain Tumor Drug Delivery (2)
- Focused Ultrasound-Enhanced Drug Delivery to Brain Tumors: Quantitative and Translational Insights from CNS Physiologically Based Pharmacokinetic Modeling. Clinical cancer research : an official journal of the American Association for Cancer Research · 27 Aug 2026 PMID 42658183
- Beyond safety: rethinking concomitant radiotherapy and trastuzumab deruxtecan in metastatic breast cancer - from feasibility to precision practice. Breast (Edinburgh, Scotland) · 18 Aug 2026 PMID 42612559
By study type
Clinical trials (1)
- Molecular evaluation of residual disease following neoadjuvant chemotherapy in triple-negative breast cancer CALGB 40603 (Alliance). The Journal of clinical investigation · 4 Aug 2026 PMID 42550611
Observational studies and case reports (4)
- Baseline Serum Albumin Is Associated With Severe Adverse Events During Trastuzumab Deruxtecan Treatment in Metastatic Breast Cancer. Anticancer research · 27 Oct 2026 PMID 42946412
- Predicting Chemoresistance in HER2-low Breast Cancer: Histologic Grade, MRI Non-mass Enhancement, and Clinical T Stage. Anticancer research · 1 Oct 2026 PMID 42823184
- Trastuzumab deruxtecan rechallenge in HER2-positive metastatic breast cancer: EN-SEMBLE. Breast (Edinburgh, Scotland) · 10 Aug 2026 PMID 42575050
- Rechallenge with zongertinib after trastuzumab deruxtecan in HER2-mutant lung cancer: A case report. Lung cancer (Amsterdam, Netherlands) · 13 Jun 2026 PMID 42287786
Human data, design not indexed (2)
- First-line treatment outcomes in HER2-altered advanced NSCLC: a real-world multi-center study comparing trastuzumab deruxtecan with conventional therapies and analysis by HER2/EGFR co-alteration status. BMC cancer · 13 Oct 2026 PMID 42864628
- Beyond safety: rethinking concomitant radiotherapy and trastuzumab deruxtecan in metastatic breast cancer - from feasibility to precision practice. Breast (Edinburgh, Scotland) · 18 Aug 2026 PMID 42612559
Preclinical: animal, cell and lab studies (4)
- ERBB2 Activating Mutations Promote Enhanced Internalization and Activity of Trastuzumab Deruxtecan in HER2-Nonamplified Metastatic Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research · 9 Sept 2026 PMID 42714867
- Focused Ultrasound-Enhanced Drug Delivery to Brain Tumors: Quantitative and Translational Insights from CNS Physiologically Based Pharmacokinetic Modeling. Clinical cancer research : an official journal of the American Association for Cancer Research · 27 Aug 2026 PMID 42658183
- Targetable S100-RAGE Signaling Mediates Intrinsic Trastuzumab Deruxtecan Resistance in Metastatic Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research · 17 Jul 2026 PMID 42467226
- EGFR S442 ectodomain mutation confers cetuximab resistance that can be overcome by ERBB2 blockade with trastuzumab-deruxtecan. Cancer letters · 23 May 2026 PMID 42176792
Written from 11 PubMed abstracts, each one listed by PMID above. Published: 2026-08-20. Drafted by language models from published abstracts; not medical advice.